Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

NCT01352273 is registered in ClinicalTrials.gov with Array Biopharma, now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT01352273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01352273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2011
Completion date
September 30, 2013
Enrollment
69 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors